Healthy
Conditions
Keywords
Sandfly, leishmaniasis, immune response, individuals age 18-50
Brief summary
Sand flies can carry the infection leishmaniasis (a parasite). The purpose of this study is to evaluate the human immune response to uninfected laboratory raised sand fly bites and select from the immune response to sand fly saliva, possible substances to use for a future vaccine to protect against the parasite leishmaniasis.
Detailed description
Based on travel history and possible exposure, subjects were entered into one of 2 arms, Ph. dubosqui or Lu. lutzomyia controlled sand fly repeated feedings. At baseline a pheresis was done to collect baseline cells. Subjects received sand fly bites on a q2 week schedule for 2 months followed by a q2 months schedule for one year. They had an option to extend for a late recall feeding at 18 months, when a skin biopsy was performed 48 hours after sand fly bites. Currently the study is fully enrolled and all human subject contact is complete. We (laboratory at NIAID) are studying the humoral, cellular immune responses using blood samples, and cytokine expression in the skin biopsy samples.
Interventions
None listed
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Uniformed Services University of the Health Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-50 * Plans to remain in DC area for at least one year * willingness to participate in all study procedures * general good health * military health care beneficiary * able to provide informed consent
Exclusion criteria
* Prior travel to geographic areas where leishmania transmitting sand flies are common * positive antibody to sand fly saliva on screening blood test * pregnancy * elevated serum IgE * history of chronic medical illness * adult history of treatment requiring anemia * large reactions to insect bites * history of multiple vasovagal reactions to phlebotomy * difficult venous access for phlebotomy * Taking medications that could interfere with immune responses
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Human Th1 immune response to specific sand fly salivary proteins | 6-18 months | Subject blood will be obtained at set points after repeated controlled sand fly feedings, duration for 20 minutes. Sand fly salivary molecules that demonstrate a strong Th1 immune response in these human PBMC, and little Th2 cytokine induction will be considered for development as future leishmania vaccine antigen candidates. |
Countries
United States
Outcome results
None listed